NRx regains Nasdaq compliance; appoints Mike Taylor director amid $25M HOPE investment term sheet

NRX Pharmaceuticals, Inc.

Received Nasdaq notice on Jan 17 that it regained MVLS compliance; requirement met on Jan 16 after 10 consecutive trading days above $35M.
Appointed Mike Taylor as Class I director, filling vacancy from Janet Rehnquist resignation, effective Jan 15.
Taylor designated by JGS Holdings per term sheet for $25M in HOPE Series A Preferred convertible into 1/3 of HOPE equity and $2M for 730k NRXP shares.
Nasdaq closed the matter, removing delisting risk from the Capital Market.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Mike Taylor

Director

NRXP · NRX Pharmaceuticals, Inc.

Effective: 2025-01-15
Filed: January 22, 2025, 6:59 PM ET

On January 15, 2025, NRx Pharmaceuticals, Inc. (the “ Company ”) appointed Mike Taylor as a Class I member of the Board of Directors of the Company (“ Board ”).

Departed

Janet Rehnquist

Director

NRXP · NRX Pharmaceuticals, Inc.

Effective: 2025-01-07
Successor: Mike Taylor
Filed: January 22, 2025, 6:59 PM ET

Mr. Taylor was appointed to fill the seat vacated as a result of the resignation from the Board of Janet Rehnquist on January 7, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Mike Taylor was appointed as Director at NRX Pharmaceuticals, Inc..

Action: appointed
Role: Director

Exact text from the filing

On January 15, 2025, NRx Pharmaceuticals, Inc. (the “ Company ”) appointed Mike Taylor as a Class I member of the Board of Directors of the Company (“ Board ”).

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Janet Rehnquist resigned as Director at NRX Pharmaceuticals, Inc..

Action: resigned
Role: Director

Exact text from the filing

Mr. Taylor was appointed to fill the seat vacated as a result of the resignation from the Board of Janet Rehnquist on January 7, 2025.

View on SEC.gov

NRX Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-25-001569

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.